ADAP vs. QURE, XERS, MGTX, IMTX, ORIC, MNMD, ANAB, KALV, PGEN, and CGEM
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include uniQure (QURE), Xeris Biopharma (XERS), MeiraGTx (MGTX), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Mind Medicine (MindMed) (MNMD), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), Precigen (PGEN), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs.
Adaptimmune Therapeutics (NASDAQ:ADAP) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
In the previous week, uniQure had 13 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 16 mentions for uniQure and 3 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.62 beat uniQure's score of -0.35 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media.
Adaptimmune Therapeutics has a net margin of -25.43% compared to uniQure's net margin of -837.80%. Adaptimmune Therapeutics' return on equity of -74.15% beat uniQure's return on equity.
Adaptimmune Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.
Adaptimmune Therapeutics presently has a consensus target price of $2.79, suggesting a potential upside of 416.20%. uniQure has a consensus target price of $38.89, suggesting a potential upside of 195.85%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Adaptimmune Therapeutics is more favorable than uniQure.
uniQure received 338 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 70.58% of users gave uniQure an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote.
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Adaptimmune Therapeutics beats uniQure on 12 of the 19 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 3/3/2025 by MarketBeat.com Staff
Free ADAP Stock Alerts